3:27 PM
 | 
Nov 02, 2018
 |  BC Extra  |  Company News

AbbVie gains Parkinson’s pipeline from BioArctic

AbbVie Inc. (NYSE:ABBV) gained exclusive, worldwide rights to a pipeline of antibodies targeting α-synuclein (SNCA) to treat Parkinson’s disease for $50 million through an option exercise with BioArctic AB (SSE:BIOA B).

The deal...

Read the full 146 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >